LetterLetter
Discontinuation of Canakinumab following Clinical Disease Remission Is Feasible in Patients with Systemic Juvenile Idiopathic Arthritis
Despoina N. Maritsi, Olga Vougiouka and Despina Eleftheriou
The Journal of Rheumatology February 2020, jrheum.190011; DOI: https://doi.org/10.3899/jrheum.190011
Despoina N. Maritsi
From the Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Medical School, National and Kapodistrian University of Athens, and Pediatric Faculty, Medical School, University of Cyprus, Nicosia, Cyprus; Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; UCL–Great Ormond Street–Institute of Child Health, Infection, Immunity, Inflammation and Physiological Medicine, London, UK. Address correspondence to Dr. D. Maritsi, Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. E-mail: dmaritsi@gmail.com
Olga Vougiouka
From the Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Medical School, National and Kapodistrian University of Athens, and Pediatric Faculty, Medical School, University of Cyprus, Nicosia, Cyprus; Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; UCL–Great Ormond Street–Institute of Child Health, Infection, Immunity, Inflammation and Physiological Medicine, London, UK. Address correspondence to Dr. D. Maritsi, Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. E-mail: dmaritsi@gmail.com
Despina Eleftheriou
From the Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Medical School, National and Kapodistrian University of Athens, and Pediatric Faculty, Medical School, University of Cyprus, Nicosia, Cyprus; Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; UCL–Great Ormond Street–Institute of Child Health, Infection, Immunity, Inflammation and Physiological Medicine, London, UK. Address correspondence to Dr. D. Maritsi, Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. E-mail: dmaritsi@gmail.com
Abstract
The optimal duration of treatment in patients with juvenile idiopathic arthritis, especially systemic JIA (sJIA), is a major concern for parents and physicians alike. Innovative medicines have managed to control this otherwise potentially life-threatening condition1. However, questions remain regarding the duration and the best timing for cessation of treatment.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 12
1 Dec 2024
Discontinuation of Canakinumab following Clinical Disease Remission Is Feasible in Patients with Systemic Juvenile Idiopathic Arthritis
Despoina N. Maritsi, Olga Vougiouka, Despina Eleftheriou
The Journal of Rheumatology Feb 2020, jrheum.190011; DOI: 10.3899/jrheum.190011